Profile data is unavailable for this security.
About the company
Inhibrx, Inc. is a clinical-stage biopharmaceutical company, which is focused on developing a broad pipeline of novel biologic therapeutic candidates. The Company’s pipeline is focused on oncology and orphan diseases. Its clinical pipeline includes therapeutic candidates, such as INBRX-101, and INBRX-109. INBRX-101 is an engineered recombinant human alpha-1 antitrypsin fragment crystallizable (AAT-Fc) fusion protein therapeutic candidate that the Company is developing for the treatment of patients with Alpha-1 Antitrypsin Deficiency (AATD) and acute Graft-versus -host-disease (aGvHD). AATD is an inherited disease that causes an increased risk of developing pulmonary disease defined by progressive loss of lung tissue and function and is associated with decreased life expectancy. INBRX-109 is an engineered tetravalent therapeutic candidate targeting death-receptor 5 (DR5), a TNFRSF member, also known as tumor necrosis factor-related apoptosis-inducing ligand or TRAIL receptor 2.
- Revenue in USD (TTM)1.80m
- Net income in USD-241.36m
- Incorporated2017
- Employees166.00
- LocationInhibrx Inc11025 N. Torrey Pines Road, Suite 200LA JOLLA 92037United StatesUSA
- Phone+1 (858) 795-4220
- Fax+1 (302) 636-5454
- Websitehttps://inhibrx.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Supernus Pharmaceuticals Inc | 607.52m | 1.32m | 1.69bn | 652.00 | 1,216.17 | 1.83 | 19.57 | 2.78 | -0.0152 | -0.0152 | 10.71 | 16.84 | 0.4077 | 0.9918 | 3.92 | 931,780.70 | 0.0883 | 4.95 | 0.1315 | 6.41 | 86.21 | 88.61 | 0.2166 | 12.84 | 1.43 | -- | 0.00 | -- | -8.95 | 8.24 | -97.83 | -58.81 | -8.17 | -- |
Catalyst Pharmaceuticals Inc | 398.20m | 71.41m | 1.74bn | 167.00 | 24.16 | 4.07 | 16.66 | 4.36 | 0.6092 | 0.6092 | 3.56 | 3.62 | 0.9417 | 4.63 | 12.45 | 2,384,455.00 | 16.89 | 25.42 | 20.06 | 29.81 | 86.95 | 85.63 | 17.93 | 30.87 | 2.68 | -- | 0.00 | 0.00 | 85.90 | 280.39 | -14.05 | -- | 20.21 | -- |
Myriad Genetics, Inc. | 753.20m | -263.30m | 1.76bn | 2.70k | -- | 2.23 | -- | 2.34 | -3.20 | -3.20 | 9.09 | 8.71 | 0.6423 | 11.22 | 6.98 | 278,963.00 | -22.45 | -- | -25.66 | -- | 68.64 | -- | -34.96 | -- | 1.87 | -342.25 | 0.0469 | -- | 11.03 | -- | -135.09 | -- | -- | -- |
Inhibrx Inc | 1.80m | -241.36m | 1.79bn | 166.00 | -- | 37.19 | -- | 991.83 | -5.03 | -5.03 | 0.0382 | 0.9184 | 0.006 | -- | 3.53 | 10,843.37 | -80.07 | -77.06 | -93.12 | -93.91 | -- | -- | -13,318.17 | -1,590.91 | -- | -11.00 | 0.8263 | -- | -17.88 | -26.85 | -66.20 | -- | 26.30 | -- |
Harmony Biosciences Holdings Inc | 617.51m | 137.70m | 1.79bn | 246.00 | 13.63 | 3.48 | 11.06 | 2.90 | 2.32 | 2.32 | 10.39 | 9.08 | 0.7906 | 25.72 | 9.34 | 2,510,207.00 | 17.63 | 7.46 | 20.83 | 9.08 | 79.28 | 80.58 | 22.30 | 10.46 | 3.07 | 31.38 | 0.2694 | 0.00 | 32.93 | -- | -28.99 | -- | -25.31 | -- |
Avadel Pharmaceuticals PLC (ADR) | 27.96m | -160.28m | 1.81bn | 154.00 | -- | 19.28 | -- | 64.69 | -2.04 | -2.04 | 0.3491 | 0.9768 | 0.188 | -- | 4.52 | 181,577.90 | -107.75 | -40.21 | -156.49 | -47.99 | 96.97 | -- | -573.17 | -374.75 | 3.36 | -13.94 | 0.00 | -- | -- | -22.99 | -16.59 | -- | -- | -- |
Fusion Pharmaceuticals Inc | 2.07m | -94.90m | 1.82bn | 113.00 | -- | 7.68 | -- | 881.29 | -1.47 | -1.47 | 0.0315 | 2.79 | 0.0082 | -- | 60.82 | 18,300.88 | -37.59 | -35.45 | -40.07 | -38.55 | -- | -- | -4,588.83 | -7,206.24 | -- | -- | 0.1352 | -- | 41.55 | -- | -8.32 | -- | 28.21 | -- |
Edgewise Therapeutics Inc | 0.00 | -100.16m | 1.82bn | 88.00 | -- | 4.31 | -- | -- | -1.57 | -1.57 | 0.00 | 4.53 | 0.00 | -- | -- | 0.00 | -28.33 | -- | -29.73 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -48.08 | -- | -- | -- |
Structure Therapeutics Inc (ADR) | 0.00 | -89.62m | 1.83bn | 93.00 | -- | 4.03 | -- | -- | -2.51 | -2.51 | 0.00 | 9.76 | 0.00 | -- | -- | 0.00 | -30.91 | -- | -33.06 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -69.62 | -- | -- | -- |
Syndax Pharmaceuticals Inc | 0.00 | -209.36m | 1.87bn | 112.00 | -- | 3.38 | -- | -- | -2.96 | -2.96 | 0.00 | 6.53 | 0.00 | -- | -- | 0.00 | -37.72 | -27.90 | -40.93 | -30.15 | -- | -- | -- | -324.34 | -- | -- | 0.00004 | -- | -- | -- | -40.19 | -- | -- | -- |
Beam Therapeutics Inc | 377.71m | -132.53m | 1.90bn | 436.00 | -- | 1.92 | -- | 5.04 | -1.87 | -1.87 | 4.90 | 12.02 | 0.2697 | -- | -- | 866,305.10 | -9.46 | -24.54 | -11.17 | -29.26 | -- | -- | -35.09 | -211.96 | -- | -- | 0.0005 | -- | 520.01 | -- | 54.16 | -- | 20.78 | -- |
Ginkgo Bioworks Holdings Inc | 251.46m | -892.87m | 1.94bn | 1.22k | -- | 1.74 | -- | 7.72 | -0.459 | -0.459 | 0.1293 | 0.5482 | 0.1196 | 24.49 | 5.01 | 206,449.10 | -42.47 | -- | -46.17 | -- | 78.52 | -- | -355.08 | -- | 6.11 | -1,703.31 | 0.00 | -- | -47.36 | -- | 57.58 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Viking Global Investors LPas of 31 Dec 2023 | 7.15m | 15.09% |
RA Capital Management LPas of 31 Dec 2023 | 4.72m | 9.97% |
Perceptive Advisors LLCas of 31 Dec 2023 | 4.26m | 8.98% |
BlackRock Fund Advisorsas of 31 Dec 2023 | 2.47m | 5.22% |
Woodline Partners LPas of 31 Dec 2023 | 2.32m | 4.89% |
The Vanguard Group, Inc.as of 31 Dec 2023 | 1.81m | 3.82% |
SSgA Funds Management, Inc.as of 31 Dec 2023 | 1.64m | 3.45% |
Vestal Point Capital LPas of 31 Dec 2023 | 1.53m | 3.23% |
Fidelity Management & Research Co. LLCas of 31 Dec 2023 | 1.47m | 3.10% |
Loomis, Sayles & Co. LPas of 31 Dec 2023 | 1.08m | 2.28% |